These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

728 related items for PubMed ID: 28497487

  • 21. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori.
    Furuta T, Yamade M, Kagami T, Uotani T, Suzuki T, Higuchi T, Tani S, Hamaya Y, Iwaizumi M, Miyajima H, Umemura K, Osawa S, Sugimoto K.
    Digestion; 2020; 101(6):743-751. PubMed ID: 31434101
    [Abstract] [Full Text] [Related]

  • 22. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
    Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW.
    Gastroenterology; 2022 Sep; 163(3):608-619. PubMed ID: 35679950
    [Abstract] [Full Text] [Related]

  • 23. Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori.
    Bunchorntavakul C, Buranathawornsom A.
    J Gastroenterol Hepatol; 2021 Dec; 36(12):3308-3313. PubMed ID: 34622504
    [Abstract] [Full Text] [Related]

  • 24. Vonoprazan: A Review in Helicobacter pylori Infection.
    Shirley M.
    Drugs; 2024 Mar; 84(3):319-327. PubMed ID: 38388872
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis of randomized controlled trials.
    Zhou BG, Mei YZ, Jiang X, Zheng AJ, Ding YB.
    Saudi J Gastroenterol; 2023 Mar; 29(6):347-357. PubMed ID: 37602635
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials.
    Sun Y, Yue L, Hu W.
    Eur J Clin Pharmacol; 2023 Feb; 79(2):279-288. PubMed ID: 36527456
    [Abstract] [Full Text] [Related]

  • 33. Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials.
    Yang C, Li S, Huang T, Lin H, Jiang Z, He Y, Yuan J, An H.
    J Clin Pharm Ther; 2022 Jul; 47(7):897-904. PubMed ID: 35247003
    [Abstract] [Full Text] [Related]

  • 34. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
    Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M.
    Gut; 2016 Sep; 65(9):1439-46. PubMed ID: 26935876
    [Abstract] [Full Text] [Related]

  • 35. Smoking and Drinking Did Not Increase the Failure of Therapeutic Helicobacter pylori Eradication by Vonoprazan, Clarithromycin, and Amoxicillin.
    Takara Y, Endo H, Nakano R, Kawachi K, Hidaka H, Matsunaga T, Tsuruoka N, Sakata Y, Shimoda R, Hara M, Fujimoto K.
    Digestion; 2019 Sep; 99(2):172-178. PubMed ID: 30179876
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors as Helicobacter pylori eradication therapy: a meta-analysis of randomized clinical trials.
    Zhang M, Pang M, Zhang M.
    Clinics (Sao Paulo); 2022 Sep; 77():100058. PubMed ID: 35810638
    [Abstract] [Full Text] [Related]

  • 39. Ten-day vonoprazan-based versus fourteen-day proton pump inhibitor-based therapy for first-line Helicobacter pylori eradication in China: A meta-analysis of randomized controlled trials.
    Gao W, Wang Q, Zhang X, Wang L.
    Int J Immunopathol Pharmacol; 2024 Sep; 38():3946320241286866. PubMed ID: 39305222
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.